Potential new therapy for dangerous middle-aged and elderly blood cancer

The drug called palbociclib may be able to prevent bone marrow scars that cannot be prevented by existing myelofibrosis treatments

"Current treatment methods can only relieve symptoms and cannot significantly improve myelofibrosis

Myelofibrosis: a dangerous cancer

Myelofibrosis is a type of leukemia

Existing treatment methods for bone marrow fibrosis cannot solve the characteristics of bone marrow scars

In two different mouse models of myelofibrosis, Palbociclib itself can reduce bone marrow scars

Combining the drug with Ruxolitinib will bring more benefits, restore bone marrow and white blood cell counts to normal levels, and significantly reduce the enlarged spleen of mice

More research is needed to determine whether these findings apply to human patients

"Combined treatments including palbociclib and ruxolitinib will be able to reduce the dose of each inhibitor, thereby reducing toxicity while improving efficacy," they wrote in a new scientific paper outlining their findings

Researchers pointed out that because ruxolitinib treatment cannot significantly reduce myelofibrosis, and long-term use often loses efficacy, new myelofibrosis treatment methods are particularly needed

Mohi said: "The findings of this study are very exciting.

Avik Dutta, Dipmoy Nath, Yue Yang, Bao T.